Last Updated: November 16, 2026

Investigational Drug Information for Onapristone

« Back to Dashboard


What is the drug development status for Onapristone?

Onapristone is an investigational drug.

There have been 11 clinical trials for Onapristone. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2023.

The most common disease conditions in clinical trials are Breast Neoplasms, Endometrial Neoplasms, and Cystadenocarcinoma, Serous. The leading clinical trial sponsors are Context Therapeutics, Memorial Sloan Kettering Cancer Center, and Context Therapeutics Inc.

There are zero US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Onapristone
TitleSponsorPhase
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast CancerContext Therapeutics Inc.PHASE1
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast CancerContext Therapeutics Inc.Phase 1/Phase 2
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)Context TherapeuticsPhase 2

See all Onapristone clinical trials

Clinical Trial Summary for Onapristone

Top disease conditions for Onapristone
Top clinical trial sponsors for Onapristone

See all Onapristone clinical trials

US Patents for Onapristone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Onapristone ⤷  Start Trial Anti-FGFR3 antibodies and methods using same Genentech Inc ⤷  Start Trial
Onapristone ⤷  Start Trial Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor The Regents of the University of California (Oakland, CA) ⤷  Start Trial
Onapristone ⤷  Start Trial Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pictilisib Genentech Inc ⤷  Start Trial
Onapristone ⤷  Start Trial Inhibition of hypoxia-inducible factor activity with carica papaya extracts The Regents of the University of California (Oakland, CA) Universiti Putra Malaysia (Selangor Darul Ehsan, MY) ⤷  Start Trial
Onapristone ⤷  Start Trial Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BEIGENE, LTD. (Grand Cayman, KY) ⤷  Start Trial
Onapristone ⤷  Start Trial Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Pharmacyclics LLC (Sunnyvale, CA) ⤷  Start Trial
Onapristone ⤷  Start Trial Antibody formulations GENENTECH, INC. (South San Francisco, CA) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Onapristone

Drugname Country Document Number Estimated Expiration Related US Patent
Onapristone Argentina AR075939 2029-03-25 ⤷  Start Trial
Onapristone Argentina AR119754 2029-03-25 ⤷  Start Trial
Onapristone Australia AU2010229994 2029-03-25 ⤷  Start Trial
Onapristone Brazil BRPI1006448 2029-03-25 ⤷  Start Trial
Onapristone Canada CA2754163 2029-03-25 ⤷  Start Trial
Onapristone China CN102378767 2029-03-25 ⤷  Start Trial
Onapristone China CN104788564 2029-03-25 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.